Dr. Wilgucki is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3800 Reservoir road NW
Washington, DC 20007
Education & Training
- University of New England College of Osteopathic MedicineClass of 2021
- Georgetown University HospitalResidency, Internal Medicine
Certifications & Licensure
- DC State License 2021 - 2024
- VA State License 2021 - 2022
Publications & Presentations
PubMed
- Consolidation ALK Tyrosine Kinase Inhibitors Versus Durvalumab or Observation After Chemoradiation in Unresectable Stage III ALK-Positive NSCLC.Amin H Nassar, Ritujith Jayakrishnan, Jamie Feng, Frances Shepherd, Elio Adib
Journal of Thoracic Oncology. 2024-09-10 - 8 citationsConsolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort St...Amin H Nassar, So Yeon Kim, Jacqueline V Aredo, Jamie Feng, Frances Shepherd
Journal of Thoracic Oncology. 2024-06-01 - Overcoming the hurdles: surmounting acquired resistance to anti-EGFR therapy in metastatic colorectal cancer.Paul E Sackstein, Nikita Chintapally, Molly Wilgucki, Marion L Hartley, Ali Alqahtani
Clinical Advances in Hematology & Oncology. 2023-11-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: